U.S. Food and Drug Administration’s Biosimilars Campaign
Over the course of six years, Palladian worked with the FDA to help inform patients and providers about biosimilar treatment options.
Challenge: The FDA needed to preserve its neutrality as a regulator while also educating and increasing awareness about biosimilars with patients and the medical community. Biosimilars are biological medications made with minor differences from an original drug, often at a lower cost with the same effectiveness.
Solution: Palladian sought to help FDA inform and empower patients through informative content deployed on social media, web pages, advertisements, stakeholder messaging, powerful graphics, and engaging videos that we created in accessible format and using jargon-free, plain language.
Results: FDA has approved more than 35 biosimilar medications to date, with more than one million Americans turning to the medications for treatment. Thanks to Palladian’s work for the FDA, patients and providers are better equipped to understand these treatment options as clinically effective and affordable. A suite of educational materials, including animated videos, infographics, and factsheets, provide tailored information vital to decision making on treatment options.